306 related articles for article (PubMed ID: 30295378)
1. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience.
Bettoli V; Manfredini M; Calamo G; Forconi R; Bencivelli D; Mantovani L; Pellacani G; Corazza M
Dermatol Ther; 2018 Nov; 31(6):e12737. PubMed ID: 30295378
[No Abstract] [Full Text] [Related]
2. Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa.
Turk D; Vellaichamy G; Lyons AB; Parks-Miller A; Nelson T; Meysami A; Hamzavi IH
Int J Dermatol; 2020 Mar; 59(3):e73-e74. PubMed ID: 31633193
[No Abstract] [Full Text] [Related]
3. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
Tzanetakou V; Stergianou D; Giamarellos-Bourboulis EJ
Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513
[No Abstract] [Full Text] [Related]
4. Low-dose adalimumab biosimilar (ZRC-3197) in the treatment of hidradenitis suppurativa.
Patil S
Indian J Dermatol Venereol Leprol; 2018; 84(6):745-747. PubMed ID: 30289113
[No Abstract] [Full Text] [Related]
5. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
6. Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic.
Benesh G; Andriano TM; Babbush KM; Hosgood HD; Cohen SR
J Cutan Med Surg; 2021; 25(4):446-448. PubMed ID: 33625899
[No Abstract] [Full Text] [Related]
7. Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013.
Sbidian E; Hotz C; Seneschal J; Maruani A; Amelot F; Aubin F; Paul C; Beylot Barry M; Humbert P; Dupuy A; Caux F; Dupin N; Modiano P; Lepesant P; Ingen-Housz-Oro S; Mahé E; Bachelez H; Chosidow O; Wolkenstein P
Br J Dermatol; 2016 Mar; 174(3):667-70. PubMed ID: 26406350
[No Abstract] [Full Text] [Related]
8. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hidradenitis suppurativa with biologic medications.
Lee RA; Eisen DB
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
[TBL] [Abstract][Full Text] [Related]
10. Cellulitis-like Sweet Syndrome caused by adalimumab therapy for severe hidradenitis suppurativa.
Canal Garcia E; Vargas Ramos JDP; Aguayo Ortiz R
Australas J Dermatol; 2020 Nov; 61(4):e448-e449. PubMed ID: 32567672
[No Abstract] [Full Text] [Related]
11. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
[TBL] [Abstract][Full Text] [Related]
12. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical psoriasiform reactions to antitumour necrosis factor-α drugs in hidradenitis suppurativa.
Dequidt L; Cogrel O; Guillet S; Milpied B; Darrigade AS; Beylot-Barry M; Pham-Ledard A
Br J Dermatol; 2018 Jan; 178(1):281-283. PubMed ID: 28444990
[No Abstract] [Full Text] [Related]
15. Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.
Nader A; Beck D; Noertersheuser P; Williams D; Mostafa N
Clin Pharmacokinet; 2017 Sep; 56(9):1091-1102. PubMed ID: 28066879
[TBL] [Abstract][Full Text] [Related]
16. Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab.
Gunter SJ; Holcomb ZE; Lam BD; Porter ML; Kimball AB
JAMA Dermatol; 2024 Jun; 160(6):678-681. PubMed ID: 38717768
[TBL] [Abstract][Full Text] [Related]
17. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Kimball AB; Okun MM; Williams DA; Gottlieb AB; Papp KA; Zouboulis CC; Armstrong AW; Kerdel F; Gold MH; Forman SB; Korman NJ; Giamarellos-Bourboulis EJ; Crowley JJ; Lynde C; Reguiai Z; Prens EP; Alwawi E; Mostafa NM; Pinsky B; Sundaram M; Gu Y; Carlson DM; Jemec GB
N Engl J Med; 2016 Aug; 375(5):422-34. PubMed ID: 27518661
[TBL] [Abstract][Full Text] [Related]
18. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.
Arenbergerova M; Gkalpakiotis S; Arenberger P
Int J Dermatol; 2010 Dec; 49(12):1445-9. PubMed ID: 21091684
[TBL] [Abstract][Full Text] [Related]
19. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
Ryan C; Sobell JM; Leonardi CL; Lynde CW; Karunaratne M; Valdecantos WC; Hendrickson BA
Am J Clin Dermatol; 2018 Jun; 19(3):437-447. PubMed ID: 29380251
[TBL] [Abstract][Full Text] [Related]
20. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
Zouboulis CC; Okun MM; Prens EP; Gniadecki R; Foley PA; Lynde C; Weisman J; Gu Y; Williams DA; Jemec GBE
J Am Acad Dermatol; 2019 Jan; 80(1):60-69.e2. PubMed ID: 29860040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
